Investors & Media

Press Release

Printer Friendly Version View printer-friendly version
<< Back
Flex Pharma Presents at the 26th International Symposium on ALS/MND

-- Study in ALS Patients with FLX-787 Expected to Initiate First Half of 2016 --

BOSTON--(BUSINESS WIRE)--Dec. 9, 2015-- Click to Tweet this News

Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for spasms associated with severe neuromuscular conditions, nocturnal leg cramps and exercise-associated muscle cramps, announced today that it will present at the 26th International Symposium on amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) in Orlando, FL on Saturday, December 12th at 6:40pm ET.

Data demonstrating GMP-synthesized single agent efficacy in significantly reducing human muscle cramp intensity in its electrically induced cramp model will be presented in the abstract titled “TRPV1 and TRPA1 Activators Reduce Muscle Cramping. Potential New Treatment For ALS Symptoms.”

“Local and topical stimulation of TRPA1 and TRPV1 in the mucous membranes by one or two activators is a potentially effective strategy to inhibit cramping,” noted National Academy of Sciences member Dr. Bruce Bean, Professor of Neurobiology at Harvard Medical School, Flex Pharma Scientific Co-Founder and Scientific Advisory Board Co-Chair. He added, “Chemical Neuro Stimulation by TRPA1 and TRPV1 activators reduces cramping induced by electrical stimulation, and we are hopeful that this approach might also alleviate cramping and spasms from disorders like ALS and MS.”

Flex Pharma plans to evaluate the effectiveness of single agent drug candidate FLX-787 as a potential treatment for cramps associated with ALS and plans to initiate a study outside the U.S. in the first half of 2016.

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for spasms associated with severe neuromuscular conditions, nocturnal leg cramps and exercise-associated muscle cramps. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma's proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers.

Flex Pharma was founded by National Academy of Sciences members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.

Individuals can follow the Company on Twitter (@flexpharma) and the Company's website (http://ir.flex-pharma.com/) to see the latest progress of the Company's pre-launch activities for its consumer product to prevent and treat exercise-associated muscle cramps.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding potential drug and consumer product candidates, the design and timing of ongoing and anticipated clinical studies and our drug development progress. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation: the status, timing, costs, results and interpretation of our clinical studies; the uncertainties inherent in conducting clinical studies; results from our ongoing and planned preclinical development; expectations of our ability to make regulatory filings and obtain and maintain regulatory approvals; results of early clinical studies as indicative of the results of future trials; the inherent uncertainties associated with intellectual property; and other factors discussed in greater detail under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent filings with the Securities and Exchange Commission (SEC). You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Source: Flex Pharma, Inc.

Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
SVP, Investor Relations & Corporate Communications
irdept@flex-pharma.com